Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies

PURPOSE: To study the impact of standard-of-care hormonal therapies on metastatic prostate cancer (mPC) clinical genomic profiles in real-world practice, with a focus on homologous recombination-repair (HRR) genes. PATIENTS AND METHODS: Targeted next-generation sequencing of 1,302 patients with mPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurita, Amado J., Graf, Ryon P., Villacampa, Guillermo, Raskina, Kira, Sokol, Ethan, Jin, Dexter, Antonarakis, Emmanuel S., Li, Gerald, Huang, Richard S. P., Casanova-Salas, Irene, Vivancos, Ana, Carles, Joan, Ross, Jeffrey S., Schrock, Alexa B., Oxnard, Geoffrey R., Mateo, Joaquin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307307/
https://www.ncbi.nlm.nih.gov/pubmed/35820087
http://dx.doi.org/10.1200/PO.22.00195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307307/
https://www.ncbi.nlm.nih.gov/pubmed/35820087
http://dx.doi.org/10.1200/PO.22.00195

Ejemplares similares